

OMB APPROVAL	
OMB Number:	3235-0287
Estimated average burden hours per response:	0.5

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

1. Name and Address of Reporting Person* <u>Casdin Partners Master Fund, L.P.</u> (Last) (First) (Middle) 1350 AVENUE OF THE AMERICAS SUITE 2600 (Street) NEW YORK NY 10019 (City) (State) (Zip)	2. Issuer Name and Ticker or Trading Symbol <u>STANDARD BIOTOOLS INC. [LAB]</u>	5. Relationship of Reporting Person(s) to Issuer (Check all applicable) <input checked="" type="checkbox"/> Director <input checked="" type="checkbox"/> 10% Owner Officer (give title below) Other (specify below)
	3. Date of Earliest Transaction (Month/Day/Year) 03/18/2024	
	4. If Amendment, Date of Original Filed (Month/Day/Year)	
Rule 10b5-1(c) Transaction Indication <input type="checkbox"/> Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.		

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned

1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price			
Common Stock	03/18/2024		A		32,525,821	A	\$2.75	44,023,749	I	See footnote ⁽¹⁾
Common Stock	03/18/2024		A		13,939,637	A	\$2.75	13,939,637	I	See footnote ⁽²⁾
Common Stock								103,556	D ⁽³⁾	
Common Stock								2,744,219	I	See footnote ⁽⁴⁾
Common Stock								1,200,000	I	See footnote ⁽⁵⁾
Common Stock								7,548,000	I	See footnote ⁽⁶⁾

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)	8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)	
				Code	V	(A)	(D)	Date Exercisable	Expiration Date						Title
Series B-1 Convertible Preferred Stock	\$2.75	03/18/2024		D			89,446	(7)	(7)	Common Stock	32,525,821	\$2.75	0	I	See footnote ⁽¹⁾
Series B-1 Convertible Preferred Stock	\$2.75	03/18/2024		D			38,334	(7)	(7)	Common Stock	13,939,637	\$2.75	0	I	See footnote ⁽²⁾

1. Name and Address of Reporting Person*
Casdin Partners Master Fund, L.P.
 (Last) (First) (Middle)
 1350 AVENUE OF THE AMERICAS
 SUITE 2600
 (Street)
 NEW YORK NY 10019
 (City) (State) (Zip)

1. Name and Address of Reporting Person*
Casdin Capital, LLC
 (Last) (First) (Middle)
 1350 AVENUE OF THE AMERICAS

SUITE 2600

(Street)

NEW YORK NY 10019

(City)

(State)

(Zip)

1. Name and Address of Reporting Person*

Casdin Partners GP, LLC

(Last)

(First)

(Middle)

1350 AVENUE OF THE AMERICAS
SUITE 2600

(Street)

NEW YORK NY 10019

(City)

(State)

(Zip)

1. Name and Address of Reporting Person*

Casdin Private Growth Equity Fund II, L.P.

(Last)

(First)

(Middle)

1350 AVENUE OF THE AMERICAS
SUITE 2600

(Street)

NEW YORK NY 10019

(City)

(State)

(Zip)

1. Name and Address of Reporting Person*

Casdin Private Growth Equity Fund II GP, LLC

(Last)

(First)

(Middle)

1350 AVENUE OF THE AMERICAS, SUITE 2600

(Street)

NEW YORK NY 10019

(City)

(State)

(Zip)

1. Name and Address of Reporting Person*

Casdin Partners FOI-MSV, LP

(Last)

(First)

(Middle)

C/O CASDIN PARTNERS GP, LLC
1350 AVENUE OF THE AMERICAS, SUITE 2600

(Street)

NEW YORK NY 10019

(City)

(State)

(Zip)

1. Name and Address of Reporting Person*

Casdin Private Growth Equity Fund, L.P.

(Last)

(First)

(Middle)

1350 AVENUE OF THE AMERICAS
SUITE 2600

(Street)

NEW YORK NY 10019

(City)

(State)

(Zip)

1. Name and Address of Reporting Person*

CASDIN PRIVATE GROWTH EQUITY FUND
GP, LLC

(Last)

(First)

(Middle)

1350 AVENUE OF THE AMERICAS
SUITE 2600

(Street)

NEW YORK	NY	10019
(City)	(State)	(Zip)
1. Name and Address of Reporting Person*		
<u>Casdin Eli</u>		
(Last)	(First)	(Middle)
1350 AVENUE OF THE AMERICAS		
SUITE 2600		
(Street)		
NEW YORK	NY	10019
(City)	(State)	(Zip)

Explanation of Responses:

- The securities are owned directly by Casdin Partners Master Fund, L.P. (the "Master Fund") and may be deemed to be indirectly beneficially owned by (i) Casdin Capital, LLC, the investment adviser to the Master Fund ("Casdin"), (ii) Casdin Partners GP, LLC, the general partner of the Master Fund (the "GP"), and (iii) Eli Casdin, the managing member of Casdin and the GP.
- The securities are owned directly by Casdin Private Growth Equity Fund II, L.P. (the "Equity Fund II") and may be deemed to be indirectly beneficially owned by (i) Casdin, the investment adviser to the Equity Fund II, and (ii) Eli Casdin, the managing member of Casdin.
- The securities are owned directly by Eli Casdin.
- The securities are owned directly by Casdin Private Growth Equity Fund, L.P. (the "Equity Fund") and may be deemed to be indirectly beneficially owned by (i) Casdin, the investment adviser to the Equity Fund, and (ii) Eli Casdin, the managing member of Casdin.
- The securities are owned directly by Casdin Partners FO1-MSV, LP ("Casdin FO1") and may be deemed to be indirectly beneficially owned by (i) Casdin, the investment adviser to Casdin FO1, (ii) the GP, the general partner of Casdin FO1, and (iii) Eli Casdin, the managing member of Casdin Capital, LLC and Casdin Partners GP, LLC.
- The securities are owned directly by CMLS Holdings II LLC ("CMLS Holdings II"). The Board of Managers of CMLS Holdings II includes Eli Casdin, who, as a member of the Board of Managers of CMLS Holdings II, shares voting and investment discretion with respect to the common stock held by CMLS Holdings II.
- Each share of the Issuer's Series B-1 Convertible Preferred Stock (the "Series B-1 Preferred Stock") was convertible at the option of the Reporting Person at any time into a number of shares of the Issuer's common stock, par value \$0.001 per share.

Remarks:

Eli Casdin has been deputized to represent the Reporting Persons on the board of directors of the Issuer. By virtue of Mr. Casdin's representation, for purposes of Section 16 of the Securities Exchange Act of 1934 (the "Exchange Act"), each of the Reporting Persons may be deemed directors by deputization of the Issuer. Each Reporting Person disclaims beneficial ownership in the securities reported on this Form 4 except to the extent of its pecuniary interest, if any, therein, and this report shall not be deemed to be an admission that such Reporting Person is the beneficial owner of such securities for purposes of Section 16 or for any other purpose.

<u>Casdin Partners Master Fund, LP By: Casdin Partners GP, LLC, its General Partner By: /s/ Eli Casdin, Managing Member</u>	<u>03/20/2024</u>
<u>Casdin Capital LLC By: /s/ Eli Casdin, Managing Member</u>	<u>03/20/2024</u>
<u>Casdin Partners GP LLC By: /s/ Eli Casdin, Managing Member</u>	<u>03/20/2024</u>
<u>Casdin Private Growth Equity Fund II, L.P. By: Casdin Private Growth Equity Fund II GP, LLC, its General Partner By: /s/ Eli Casdin, Managing Member</u>	<u>03/20/2024</u>
<u>Casdin Private Growth Equity Fund II GP, LLC By: /s/ Eli Casdin, Managing Member</u>	<u>03/20/2024</u>
<u>Casdin Partners FO1-MSV, LP By: Casdin Partners GP, LLC, its General Partner By: /s/ Eli Casdin, Managing Member</u>	<u>03/20/2024</u>
<u>Casdin Private Growth Equity Fund, L.P. By: Casdin Private Growth Equity Fund II GP, LLC, its General Partner, By: /s/ Eli Casdin, Managing Member</u>	<u>03/20/2024</u>
<u>Casdin Private Growth Equity Fund GP, LLC, By: /s/ Eli Casdin, Managing Member, /s/ Eli Casdin, Eli Casdin</u>	<u>03/20/2024</u>
<u>/s/ Eli Casdin</u>	<u>03/20/2024</u>
** Signature of Reporting Person	Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.